Evidence map›Paper›PMID 34136357›Full record

ArticleMolecular genetics and metabolism reports2021

Open-label phase 1/2 study of vestronidase alfa for mucopolysaccharidosis VII.

Simon Jones, Mahmut Coker, Antonio González-Meneses López, Jennifer Sniadecki, Jill Mayhew, Pauline Hensman, Agnieszka Jurecka

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics and metabolism reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Mucopolysaccharidoses and the blood-brain barrier.Fluids and barriers of the CNS · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Simon JonesManchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK.
Mahmut CokerEge University, Bornova, Izmir, Turkey.
Antonio González-Meneses LópezHospital Universitario Virgen del Rocío, Sevilla, Spain.
Jennifer SniadeckiUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Jill MayhewUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Pauline HensmanManchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK.
Agnieszka JureckaUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Ultragenyx Pharmaceutical (United States) · USEge University · TRHospital Universitario Virgen del Rocío · ESSt Mary's Hospital · GBSt. Mary's Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vestronidase alfa is an enzyme replacement therapy for mucopolysaccharidosis VII (MPS VII). In this open-label, phase 1/2 study, three subjects with MPS VII received intravenous vestronidase alfa administered every other week (QOW) for 14 weeks (2 mg/kg), followed by 24-week forced-dose titration (1, 4, and 2 mg/kg QOW; 8 weeks each), 36-week continuation (2 mg/kg), and long-term extension (4 mg/kg). Vestronidase alfa was well tolerated and led to dose-responsive, sustained reductions in urinary glycosaminoglycan excretion.

Indexed as

Enzyme replacement therapyMPS VIIMucopolysaccharidosis VIIPhase 1/2Recombinant human β-glucuronidaseVestronidase alfa

Identifiers

PMID34136357
PMCPMC8178115
OpenAlexW3169109667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.